India's Gennova working on Omicron-specific COVID-19 vaccine - source




  • In US
  • 2022-01-17 04:40:47Z
  • By Reuters
 

NEW DELHI (Reuters) - India's Gennova Biopharmaceuticals is working on an Omicron-specific COVID-19 vaccine candidate that could be ready in a month or two, a person with direct knowledge of the matter told Reuters.

The source, who did not want to be named as the information was private, said the product might need a small trial in India before it could be rolled out as a booster or standalone vaccine.

A representative for Gennova, a unit of drugmaker Emcure Pharmaceuticals that does business in some 70 countries, did not immediately respond to a request for comment.

Pfizer Inc said last week https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-ceo-says-omicron-variant-targeted-vaccine-is-most-likely-outcome-2022-01-10 a redesigned COVID-19 vaccine that specifically targets the Omicron coronavirus variant could be ready to launch by March.

The source said Gennova on Friday separately submitted to India's drug regulator phase 2 trial data for its original mRNA vaccine candidate. The government said https://www.pib.gov.in/PressReleasePage.aspx?PRID=1748520 last year that product was found to be "safe, tolerable, and immunogenic" in the participants of an initial study.

If given emergency-use approval, this would be the country's first mRNA COVID-19 vaccine like the ones developed by Pfizer and Moderna.

(Reporting by Krishna N. Das; Editing by Kenneth Maxwell)

COMMENTS

More Related News

Ukraine Latest: US Seeks to Steer India Away From Russian Arms
Ukraine Latest: US Seeks to Steer India Away From Russian Arms

(Bloomberg) -- The US is preparing a military aid package for India that aims at increasing security ties and reducing its reliance on Russian weapons...

Aramco-Style Dividend Is What LIC Investors Seek Post Flop Debut
Aramco-Style Dividend Is What LIC Investors Seek Post Flop Debut

(Bloomberg) -- Disappointed by a 7.8% plunge that made for the world's second-worst trading debut among large IPOs this year, shareholders of state-run Life ...

US urges India to reverse ban on wheat exports
US urges India to reverse ban on wheat exports
  • World
  • 2022-05-17 08:33:11Z

The United States hopes India will reverse its ban on wheat exports, Washington's top diplomat to the United Nations said Monday, warning the move would...

Insurer LIC Slumps in Debut After Record $2.7 Billion India IPO
Insurer LIC Slumps in Debut After Record $2.7 Billion India IPO

(Bloomberg) -- State-run insurer Life Insurance Corporation of India dropped early in its Mumbai trading debut after a record initial public offering that...

NFHS-5: India
NFHS-5: India's preference for sons over daughters remains

Nearly 80% of those who took part in a government survey said they wanted at least one son in their lifetime.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: US